Welcome to Macroaxis
Sign in to go to your portfolios
Don't have an account? Create It
  Macroaxis: Personalized Investing   The proven technology to invest wisely
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
  
 
US Market Closed: May 26, 15:22 PM 2012  
JNJ PFE NVS GSK ABT SNY 
 
 
  NYSE  7,534  18.032  Index Moved Down 



Processing
Collecting data for MRK

Merck quote and profile

    
37.55
  
STOCK
(0.05)  Macroaxis: -0.13 Down   0.13%  
 29.47 Year To Date 39.5 
 37.37 Trading Day  37.75 

Diversification Suggestion

Use Merck to protect against small markets fluctuations. The stock experiences normal downward trend and little activity

1 Month Beta ..........

0.16
As returns on market increase, Merck returns are expected to increase less than the market. However during bear market, the loss on holding Merck will be expected to be smaller as well.
Merck & Inc. Small Beta
Current Valuation116.8 B
Shares Outstanding3.04 B
Number of Shares Shorted19.26 M
Revenue48.2 B
 United States NASDAQ   0.07 % Macroaxis: 0.07 Moved Down  
 
 thisRed MRK MRK agains markets  0.13 % Macroaxis: 0.13 Moved Down  
 
 United States SP 500   0.22 % Macroaxis: 0.22 Moved Down  
 
 United States NYSE   0.24 % Macroaxis: 0.24 Moved Down  
 

Merck Leadership

Kenneth Frazier Chairman, CEO and President and President of Global Human Health
Peter Kim Executive VP and President of Merck Research Laboratories, Ph.D
Mirian Graddick-Weir Executive Vice President - Human Resources
Willie Deese Executive Vice President and President - Merck Manufacturing Division

Merck Price and Market Media

The median price of Merck for the period between Thu, Apr 26, 2012 and Sat, May 26, 2012 is 38.22 with a coefficient of variation of 1.68. The daily time series for the period is distributed with a sample standard deviation of 0.64, arithmetic mean of 38.24, and mean deviation of 0.53. The Stock received substential amount of media coverage during this period.
Merck         Market
Price Growth (%)
 
Timeline
Test_All_Boomers_for_Hepatitis_C,_Urges_CDCTest All Boomers for Hepatitis C, Urges CDC05/18/2012Macroaxis: News
Pharmacyclics_NASDAQ_PCYC_Reports_Clinical_Abstracts_at_ASCO_–_PCYC,_SPPI_<b><-b>Pharmacyclics (NASDAQ:PCYC) Reports Clinical Abstracts at ASCO ? PCYC, SPPI ...05/21/2012Macroaxis: News
Merck__and_amp;_Co_Inc_Announces_Third-Quarter_2012_DividendMerck & Co Inc Announces Third-Quarter 2012 Dividend05/22/2012Macroaxis: Reuters News
Drugmakers_vulnerable_if_US_health_law_revokedDrugmakers vulnerable if U.S. health law revoked05/24/2012Macroaxis: Reuters News
Reports__Sanofi,_Merck_Bid_At_Least_$25_Per_Share_For_AmylinReports: Sanofi, Merck Bid At Least $25 Per Share For Amylin05/25/2012Macroaxis: Barrons  News

Merck Summary

Merck & Inc. [MRK] is traded on American Stock Exchange in USA. It is located in Whitehouse Station, NJ and employs 86,000 people. The company currently falls under 'Mega-Cap' category with total capitalization of 114.21 B. Merck & Inc. runs under Healthcare sector within Drug Manufacturers - Major industry. This company has 3.04 B outstanding shares of which 19.26 M shares are now shorted by investors with about 1.5 days to cover shorted positions.

Merck Liquidity

MERCK CO INC has about 15.57 B in cash with 12.82 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12.
The company has 18.16 B in debt with debt to equity (D/E) ratio of 0.32 which is OK given its current industry classification. Merck & Inc. has Current Ratio of 2.03 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Discuss Merck quote and profile

       
       
    
    
Merck
Performance
0
Out Of
100
Over 30
Days
Over the last 30 days Merck & Inc. has generated negative risk-adjusted returns adding no value to investors with long positions.
    
    

Promote Merck

    
Follow Merck with your standard RSS feed, custom widget, or your favorite social app
Add To Reader
 
Add Merck to your reader
 
Get social with Merck
 Get social with Merck 
Share Toggle social options for Merck
    

Add Merck to Your Portfolio

    
Sign in to add this equity to your portfolios   
  
 
    

Merck Research Report

    
    

Merck Executives

Peter Kellogg CFO and Executive VP

Merck Directors

Steven Goldstone Independent Director
Thomas Glocer Independent Director
Thomas Cech Independent Director, Ph.D
William Harrison Lead Independent Director
Harry Jacobson Independent Director



 

 
Analytics
Investor Landscape
Efficient Frontier
Market Correlation
Risk and Return Analysis
Financial Content
Portfolio Projections
Portfolio Backtesting
Tools
FAQs
Retirement Optimizer
RSS and Mobile Access
Company Directory
Advisor Directory
Insider Directory
Wealth Management
About Us
About Macroaxis
Contact Us
Terms Of Use
Privacy Policy
Custom Reporting
Product Tour
More ROI Custom Reporting